NYSE · A
Agilent Technologies, Inc.
Healthcare · Medical - Diagnostics & Research
$173.07▼ 0.47% ($0.82)at close
Pre-market$173.17▲ 0.06%4:39 AM ET
Valuation
Cash-flow DCF
Verdict: fairly priced. Price above Base.
The price needs 28.3% free cash flow growth a year for 5 years. Our scenarios assume −3.0–25.0%.
That's 2.4× its past 10-year pace.
Value per share
Base case
$88.31
Price used $173.07 is 2.0× this
USD · TTM ending Jul 31, 2026 · Price Oct 23, 8:02 PM UTC
Free cash flow each value needs
Free cash flow today $1B. The price needs $5B by 2036. Base case: $2.5B. At its recent pace: $3.2B. Bear to Bull: $1.1B to $6.1B.
Free cash flow today $1B. The price needs $5B by 2036. Base case: $2.5B. At its recent pace: $3.2B. Bear to Bull: $1.1B to $6.1B.
Free cash flow in 2036
today $1B
+$2.5Bmore than the Base case · 2.0×
Value per share · Base case
$88.31
Price $173.07
2.0× this
- Stage 1 growth, yrs 1–5
- 12.0%
- Stage 2 growth, yrs 6–10
- 6.6%
- Discount rate
- 9.5%
USD · TTM ending Jul 31, 2026 · Price Oct 23, 8:02 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 17.37% over the last year. Revenue grew 8.6% over the trailing twelve months. Operating margin moved from 21.27% to 22.23%. Free cash flow grew 31.99% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/FCF range (73rd percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at 22.23% — continued expansion would be needed to justify the premium. Revenue growth of 8.6% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Return analysis
Company profile
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries.
Market multiples
Stock splits
Every 500 shares became 699
Profitability & growth
Analyst consensus
33
Buy
7
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 23, 2026
Q4 FY26 · EPS est $1.72 · Revenue est $2.0B
Same quarter, year over year
FY26 YTD +12.0%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q3 combined $4.47 vs $3.99 · all 3 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
FY25
FY24
FY23
—
—
—
—
Fiscal year totals
- FY25
- $5.58
- +5.5%
- FY24
- $5.29
- —
Q3 FY26
Reported Aug 26, 2026 · Latest
HoverTap a cell to inspect
Actual
$1.62
Estimate
$1.49
Year over year
+18.2%
Vs prior quarter
+8.7%
Institutional Sentiment
Agilent Technologies, Inc. · A
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.